Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | GRN | P28799 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22739234 | 0.87 | TSHR (0.40) | TSHRKMOHPGDSLC6A2SLC6A4 | |
| SCHEMBL22739243 | 0.83 | TSHR (0.35) | TSHRHPGDMEN1KMT2ASLC6A2 | |
| SCHEMBL22727569 | 0.72 | TSHR (0.43) | TSHRHPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22727335 | 0.71 | TSHR (0.44) | TSHRHPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6568396 | 0.64 | TSHR (0.53) | TSHRKMOHPGDMEN1KMT2A | |
| SCHEMBL3365999 | 0.64 | TSHR (0.52) | TSHRKMOHPGDSLC6A2SLC6A4 | |
| SCHEMBL11785050 | 0.63 | TSHR (0.55) | TSHRHPGDSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11218358 | 0.63 | TSHR (0.57) | TSHRKMOHPGDSLC6A2SLC6A4 | |
| SCHEMBL11782048 | 0.62 | TSHR (0.54) | TSHRKMOHPGDSLC6A2SLC6A4 | |
| SCHEMBL11782487 | 0.62 | TSHR (0.50) | TSHRKMOHPGDSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020243142-A1 | FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTS | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |